Drug Development Research publishes research papers and review-type articles covering all area within drug development: from target identification and validation and structure–activity relationship studies, through to post-market clinical reports.
Topics covered include but are not limited to medicinal and process chemistry, pharmacology, biotechnology and biopharmaceuticals, toxicology, drug delivery, formulation, pharmacokinetics, clinical trial reviews and post-approval/post-marketing evaluation. The journal also welcomes manuscripts on new compounds and technologies in all areas focused on human therapeutics, as well as global management, health care policy and strategy, and regulatory issues that involve drug discovery and development.
Each submission is categorized in to one of the following sub-sections of DDR:
Hit, Lead & Candidate Discovery
e.g., target identification and validation, drug design, SAR studies, lead identification and optimization, etc.
Preclinical Research & Development
e.g., in vitro and in vivo evaluation of pharmacodynamics, pharmacokinetics, ADME, safety, toxicology, formulation, drug delivery, etc.
Clinical Research
e.g., Phases I–III clinical trials, trial material manufacturing (process chemistry), quality control/assurance, etc.
Post-Market Research
e.g., Phase IV clinical trials, post-market safety monitoring, off-label investigations, etc.
Enabling Technologies
e.g., genomics, metabolomics, proteomics, etc.
Strategy, Management & Health Policy
e.g., drug pricing and access, health care provision, etc.
Articles are considered for publication based on the aforementioned scope and the quality of the science reported. Only articles reporting rigorously conducted research and offering advancement to the scientific literature will be considered.